EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 3, 2019
Media advisory: To contact the U.S. Preventive Services Task Force, email the Media Coordinator at Newsroom@USPSTF.net or call 202-572-2044. The full report, related articles and podcast are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time and all USPSTF articles remain free indefinitely: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.11885?guestAccessKey=2cee0cc3-712b-4d98-819b-0ad8d900551e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090319
Bottom Line: The U.S. Preventive Services Task Force (USPSTF) added aromatase inhibitors to its recommendation that clinicians offer medications to reduce the risk of breast cancer (tamoxifen, raloxifene or aromatase inhibitors) to asymptomatic women 35 and older, including those with previous benign breast lesions, who are at increased risk of developing the disease but at low risk for adverse effects from the medications. The USPSTF recommends against routine use of these medications in women not at increased risk for breast cancer. This recommendation doesn’t apply to women who have a current or previous diagnosis of breast cancer or ductal carcinoma in situ. This statement is an update of its 2013 recommendation.
The USPSTF Concludes:
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Note: More information about the U.S. Preventive Services Task Force, its process, and its recommendations can be found on the newsroom page of its website.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.